Human Longevity, Inc. is a technology company that uses precision medicine and artificial intelligence to develop health risk and recommendation platforms aimed at reducing biological age and extending lifespan.

Actym Therapeutics develops a new drug modality using genetically modified bacteria to initiate a selective immune response within the tumor microenvironment for treating solid tumors.